A Phase 2 interventional study of Lidoderm (Lidocaine 5% Patch) and Placebo Patch in Osteoarthritis of the Knee, sponsored by Endo Pharmaceuticals. Completed at 20 sites in United States. Open to participants aged 37 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 186th largest by enrollment of the 691 interventional ones that give a count, is one of 19 that started in 2007, is one of 111 in phase 2, and was the 58th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Lucas R. Cusumano, MD · Sites in United States
Ages 40+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
VA Office of Research and Development · Sites in United States
Ages 45–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 37 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 19 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 565 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 5 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
54 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Add all 54 to your calendar (.ics) → With an account.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with knee pain due to Osteoarthritis (OA) experiencing sub-optimal pain relief from their current analgesic regimen will participate in a pilot clinical trial to evaluate the effectiveness and tolerability of the Lidoderm Patch compared with placebo in treating knee pain from OA.
Key Inclusion criteria:
Key Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
Drug: Lidoderm (Lidocaine 5% Patch)
Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
Drug: Placebo Patch
Topical Patch
Also known as: Lidoderm
Topical Patch
Also known as: Placebo
Time-to-Exit From Current Study Treatment
Time-to-exit was defined as the number of days at which a patient either met the switching criterion \[a 2-category change in the Pain Relief Scale (PRS) score in the worsening direction (increasing pain or decreasing pain relief) for 2 consecutive days\] or discontinued from the study. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. Traditional survival models that consider event times (e.g. median survival time) as independent and homogeneous across patients were not suitable for this study.
Time frame: Baseline, Period 1 (up to 4 weeks ±2 days), Period 2 (up to 4 weeks ±2 days), Period 3 (up to 4 weeks ±2 days), or Premature Discontinuation
Time-to-Exit Due to Lack of Efficacy
Time-to-exit due to lack of efficacy was defined as a patient that met the switching criterion (a 2-category change in Pain Relief Scale (PRS) in the worsening direction \[increasing pain or decreasing pain relief\] for 2 consecutive days) or was discontinued from the current period or study due to lack of efficacy. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. No patients discontinued from the study due to lack of efficacy.
Time frame: Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Exit Status From Current Study Treatment - Yes
Exit status from a current study treatment was categorized as yes or no for patients who exited prior to the 4-week planned duration. This analysis supports the results of the primary analysis. The number of patients exiting (yes) is reported.
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Intensity Numerical Rating Scale (PI-NRS)
The Numerical Rating Scale (NRS) is an 11-point categorical rating scale to assess pain intensity (PI-NRS); 0= no pain and 10= worst possible pain. The scale is anchored on the left with "No Pain" and on the right with "Worst Possible Pain." Patients were to complete this assessment at approximately the same time each day during the double-blind treatment period in their e-diary. The overall treatment difference for the Lidoderm (lidocaine patch 5%) and placebo patch was compared by combining data for patients receiving the respective treatment regardless of the randomized study sequence.
Time frame: Baseline, End of Period 1 (up to 4 weeks), End of Period 2 (up to 4 weeks) and End of Period 3 (up to 4 weeks)
Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Relief Scale (PRS) Scores
The Pain Relief Scale (PRS) is a 9-point categorical rating scale to assess pain relief during the 24-hours since the last assessment; 0= completely worse and 8= complete pain relief. Patients completed this assessment each day during the run-in period and each day during the double-blind treatment phase in their e-diary.
Time frame: Baseline, End of Period 1 (up to 4 weeks), End of Period 2 (up to 4 weeks) and End of Period 3 (up to 4 weeks)
Overall Treatment Difference of the LSMeans of the Pain Quality Assessment Scale (PQAS) Scores
The PQAS measures individual pain qualities and the impact of treatment on those qualities. Items 1-19 are each rated on an 11-point scale ranging from 0 (lowest score - no pain of that type) to 10 (highest score - the highest level of that type of pain). Average surface pain = average of PQAS items: cold, sensitive, itchy, numb, and tingling. Average deep pain = average of PQAS items: dull, cramping, throbbing, aching, and heavy. Average paroxymal pain = average of PQAS items: sharp, shooting, electric, and radiating.
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Patient Global Impression of Change From Baseline in Osteoarthritis (OA) Pain
Patients rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale indicating: "very much worse" (0); "much worse" (1); "minimally worse" (2); "no change" (3); "minimally improved" (4); "much improved" (5); and "very much improved" (6).
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Investigator Global Impression of Change From Baseline in Osteoarthritis (OA) Pain
Investigators rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale ranging from "very much worse" to "very much improved." A similar questionnaire was completed by the Investigator.
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Patient Global Assessment of Treatment Satisfaction
At the end of each period, patients rated their overall satisfaction with study treatment using a 5-point categorical scale indicating: 0 - very dissatisfied; 1 - dissatisfied; 2 - no preference; 3 - satisfied; and 4 - very satisfied.
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Investigator Global Assessment of Treatment Satisfaction
At the end of each period, investigators rated their overall satisfaction with study treatment using a 5-point categorical scale ranging from 0 (very dissatisfied) to 4 (very satisfied).
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Overall Treatment Difference in LSMeans of Beck Depression Inventory Second Edition (BDI-II) Total Score
The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.
Time frame: Baseline and end of treatment period (up to 4 weeks)
Quality of Life: Four Category Beck Depression Inventory Second Edition (BDI-II) Composite Score
The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.
Time frame: Screening, Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Index Scores
Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline (Day 0) and at each clinic visit (at least every 4 weeks) or at premature discontinuation. Values of the EQ-5D index score range from -1 (worst) to 1 (best).
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Health Status Today Using a Visual Analog Scale (VAS)
Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Values of the continuous EQ-5D health state today (VAS) ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Quality of Life: Three-Category EuroQol Quality of Life Instrument (EQ-5D) General Health Today Compared to Last 12 Months
Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Categories included Better, Much the Same, and Worse.
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Overall Treatment Difference in LSMeans for Verran Snyder-Halpern (VSH) Sleep Scale
The VSH Sleep Scale is contained in a 15 item self-report instrument that measures the quality of a patient's sleep over the last 24 hours. Each item is scored on a 0-100 visual analog scale. The VSH is categorized into 3 sleep scales: disturbance (which measures delays and interruptions in sleep)\[maximum score = 700\], effectiveness (which measures how well sleep refreshed the individual) \[maximum score = 600\], and supplementation (which measures the need for napping) \[maximum score = 400\]. The higher the score the greater the value of the sleep characteristic for that patient.
Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
This exploratory, Phase IIb study was initiated on March 6, 2007 at 21 study centers in the United States and completed on June 24, 2008.
| Milestone | Run-in Period: Lidoderm | Treatment Sequence: Lidoderm - Placebo - Placebo | Treatment Sequence: Placebo - Lidoderm - Lidoderm |
|---|---|---|---|
| Started | 169 | 0 | 0 |
| Completed | 93 | 0 | 0 |
| Not completed | 76 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Did not qualify for randomization | 54 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 0 | 0 |
| Withdrew: Informed consent withdrawn | 4 | 0 | 0 |
| Milestone | Run-in Period: Lidoderm | Treatment Sequence: Lidoderm - Placebo - Placebo | Treatment Sequence: Placebo - Lidoderm - Lidoderm |
|---|---|---|---|
| Started | 0 | 50 | 43 |
| Completed | 0 | 48 | 41 |
| Not completed | 0 | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Milestone | Run-in Period: Lidoderm | Treatment Sequence: Lidoderm - Placebo - Placebo | Treatment Sequence: Placebo - Lidoderm - Lidoderm |
|---|---|---|---|
| Started | 0 | 48 | 41 |
| Completed | 0 | 47 | 39 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 1 |
| Milestone | Run-in Period: Lidoderm | Treatment Sequence: Lidoderm - Placebo - Placebo | Treatment Sequence: Placebo - Lidoderm - Lidoderm |
|---|---|---|---|
| Started | 0 | 47 | 39 |
| Completed | 0 | 46 | 38 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
Time-to-exit was defined as the number of days at which a patient either met the switching criterion \[a 2-category change in the Pain Relief Scale (PRS) score in the worsening direction (increasing pain or decreasing pain relief) for 2 consecutive days\] or discontinued from the study. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. Traditional survival models that consider event times (e.g. median survival time) as independent and homogeneous across patients were not suitable for this study.
| Days | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| Period 1 ( Sequence LPP, N=21; Sequence PLL, N=21) | 31 (10 to 31) | 20 (12 to 30) |
| Period 2 (Sequence LPP, N=19; Sequence PLL, N=20) | NA (NA to NA) | NA (NA to NA) |
| Period 3 (Sequence LPP, N=19; Sequence PLL, N=19) | NA (19 to NA) | NA (NA to NA) |
Time-to-exit due to lack of efficacy was defined as a patient that met the switching criterion (a 2-category change in Pain Relief Scale (PRS) in the worsening direction \[increasing pain or decreasing pain relief\] for 2 consecutive days) or was discontinued from the current period or study due to lack of efficacy. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. No patients discontinued from the study due to lack of efficacy.
| days | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| Period 1 (Sequence LPP, N=21; Sequence PLL, N=21) | NA (NA to NA) | NA (NA to NA) |
| Period 2 (Sequence LPP, N=19; Sequence PLL, N=20) | NA (NA to NA) | NA (NA to NA) |
| Period 3 (Sequence LPP, N=19; Sequence PLL, N=19) | NA (NA to NA) | NA (NA to NA) |
Exit status from a current study treatment was categorized as yes or no for patients who exited prior to the 4-week planned duration. This analysis supports the results of the primary analysis. The number of patients exiting (yes) is reported.
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| Period 1 (Sequence LPP, N=21; Sequence PLL, N=21) | 10 | 12 |
| Period 2 (Sequence LPP, N=19; Sequence PLL, N=20) | 5 | 4 |
| Period 3 (Sequence LPP, N=19; Sequence PLL, N=19) | 6 | 2 |
The Numerical Rating Scale (NRS) is an 11-point categorical rating scale to assess pain intensity (PI-NRS); 0= no pain and 10= worst possible pain. The scale is anchored on the left with "No Pain" and on the right with "Worst Possible Pain." Patients were to complete this assessment at approximately the same time each day during the double-blind treatment period in their e-diary. The overall treatment difference for the Lidoderm (lidocaine patch 5%) and placebo patch was compared by combining data for patients receiving the respective treatment regardless of the randomized study sequence.
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Intensity Numerical Rating Scale (PI-NRS) | 3.03 ± 0.35 | 3.57 ± 0.35 |
The Pain Relief Scale (PRS) is a 9-point categorical rating scale to assess pain relief during the 24-hours since the last assessment; 0= completely worse and 8= complete pain relief. Patients completed this assessment each day during the run-in period and each day during the double-blind treatment phase in their e-diary.
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Relief Scale (PRS) Scores | 4.45 ± 0.25 | 4.06 ± 0.25 |
The PQAS measures individual pain qualities and the impact of treatment on those qualities. Items 1-19 are each rated on an 11-point scale ranging from 0 (lowest score - no pain of that type) to 10 (highest score - the highest level of that type of pain). Average surface pain = average of PQAS items: cold, sensitive, itchy, numb, and tingling. Average deep pain = average of PQAS items: dull, cramping, throbbing, aching, and heavy. Average paroxymal pain = average of PQAS items: sharp, shooting, electric, and radiating.
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Intense | 3.31 ± 0.32 | 3.53 ± 0.32 |
| Sharp | 2.50 ± 0.34 | 3.00 ± 0.34 |
| Hot | 1.12 ± 0.26 | 1.59 ± 0.27 |
| Dull | 3.04 ± 0.33 | 3.28 ± 0.33 |
| Cold | 0.62 ± 0.14 | 0.50 ± 0.14 |
| Sensitive | 0.88 ± 0.20 | 0.96 ± 0.21 |
| Tender | 2.08 ± 0.30 | 1.89 ± 0.30 |
| Itchy | 0.90 ± 0.23 | 1.00 ± 0.23 |
| Shocking | 1.95 ± 0.34 | 2.36 ± 0.34 |
| Numb | 1.31 ± 0.28 | 1.52 ± 0.28 |
| Electrical | 1.32 ± 0.29 | 1.26 ± 0.30 |
| Tingling | 1.24 ± 0.26 | 1.24 ± 0.26 |
| Cramping | 1.78 ± 0.33 | 2.03 ± 0.33 |
| Radiating | 2.03 ± 0.35 | 2.10 ± 0.35 |
| Throbbing | 2.24 ± 0.34 | 2.06 ± 0.35 |
| Aching | 2.78 ± 0.36 | 3.22 ± 0.37 |
| Heavy | 2.12 ± 0.34 | 2.26 ± 0.34 |
| Overall unpleasantness | 2.98 ± 0.34 | 3.55 ± 0.35 |
| Intense deep pain | 3.33 ± 0.37 | 3.77 ± 0.37 |
| Intense surface pain | 1.61 ± 0.28 | 1.82 ± 0.29 |
| Average surface pain | 0.99 ± 0.15 | 1.05 ± 0.15 |
| Average deep pain | 2.38 ± 0.29 | 2.55 ± 0.29 |
| Average paroxysmal pain | 1.78 ± 0.25 | 2.06 ± 0.25 |
Patients rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale indicating: "very much worse" (0); "much worse" (1); "minimally worse" (2); "no change" (3); "minimally improved" (4); "much improved" (5); and "very much improved" (6).
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| 6-Very Much Impr, Period 1 (LPP, N=21; PLL, N=21) | 3 | 5 |
| 6-Very Much Impr., Period 2 (LPP, N=19; PLL, N=20) | 3 | 2 |
| 6-Very Much Impr., Period 3 (LPP, N=19; PLL, N=19) | 4 | 4 |
| 5-Much Improved, Period 1 (LPP, N=21; PLL, N=21) | 6 | 8 |
| 5-Much Improved, Period 2 (LPP, N=19; PLL, N=20) | 9 | 8 |
| 5-Much Improved, Period 3 (LPP, N=19; PLL, N=19) | 8 | 10 |
| 4-Mini. Improved, Period 1 (LPP, N=21; PLL, N=21) | 7 | 4 |
| 4-Mini. Improved, Period 2 (LPP, N=19; PLL, N=20) | 3 | 6 |
| 4-Mini. Improved, Period 3 (LPP, N=19; PLL, N=19) | 3 | 3 |
| 3-No Change, Period 1 (LPP, N=21; PLL, N=21) | 5 | 1 |
| 3-No Change, Period 2 (LPP, N=19; PLL, N=20) | 1 | 2 |
| 3-No Change, Period 3 (LPP, N=19; PLL, N=19) | 4 | 2 |
| 2-Minimally Worse, Period 1 (LPP, N=21; PLL,N=19) | 0 | 3 |
| 2-Minimally Worse, Period 2 (LPP, N=19; PLL, N=20) | 1 | 1 |
| 2-Minimally Worse, Period 3 (LPP, N=19; PLL, N=19) | 0 | 0 |
| 1-Much Worse, Period 1 (LPP, N=21; PLL, N=21) | 0 | 0 |
| 1-Much Worse, Period 2 (LPP, N=19; PLL, N=20) | 2 | 0 |
| 1-Much Worse, Period 3 (LPP, N=19; PLL, N=19) | 0 | 0 |
| 0-Very Much Worse, Period 1 (LPP,N=21; PLL, N=21) | 0 | 0 |
| 0-Very Much Worse, Period 2 (LPP, N=19; PLL, N=20) | 0 | 1 |
| 0-Very Much Worse, Period 3 (LPP, N=19; PLL, N=19) | 0 | 0 |
Investigators rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale ranging from "very much worse" to "very much improved." A similar questionnaire was completed by the Investigator.
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| 6-Very Much Impr, Period 1 (LPP, N=21; PLL, N=21) | 3 | 4 |
| 6-Very Much Impr, Period 2 (LPP, N=19; PLL, N=20) | 2 | 3 |
| 6-Very Much Impr, Period 3 (LPP, N=19; PLL, N=19) | 5 | 4 |
| 5-Much Improved, Period 1 (LPP, N=21; PLL, N=21) | 7 | 9 |
| 5-Much Improved, Period 2 (LPP, N=19; PLL, N=20) | 10 | 8 |
| 5-Much Improved, Period 3 (LPP, N=19; PLL, N=19) | 7 | 8 |
| 4-Min. Improved, Period 1 (LPP, N=21; PLL, N=21) | 4 | 2 |
| 4-Min. Improved, Period 2 (LPP, N=19; PLL, N=20) | 3 | 7 |
| 4-Min. Improved, Period 3 (LPP, N=19; PLL, N=19) | 4 | 4 |
| 3-No Change, Period 1 (LPP, N=21; PLL, N=21) | 3 | 2 |
| 3-No Change, Period 2 LPP, N=19; PLL, N=20) | 0 | 1 |
| 3-No Change, Period 3 (LPP, N=19; PLL, N=19) | 1 | 2 |
| 2-Minimally Worse, Period 1 (LPP, N=21; PLL, N=21) | 3 | 3 |
| 2-Minimally Worse, Period 2 (LPP, N=19; PLL, N=20) | 1 | 0 |
| 2-Minimally Worse, Period 3 (LPP, N=19; PLL, N=19) | 0 | 1 |
| 1-Much Worse, Period 1 (LPP, N=21; PLL, N=21) | 1 | 1 |
| 1-Much Worse, Period 2 (LPP, N=19; PLL, N=20) | 3 | 0 |
| 1-Much Worse, Period 3 (LPP, N=19; PLL, N=19) | 1 | 0 |
| 0-Very Much Worse, Period 1 (LPP, N=21; PLL, N=21) | 0 | 0 |
| 0-Very Much Worse, Period 2 (LPP, N=19; PLL, N=20) | 0 | 1 |
| 0-Very Much Worse, Period 3 (LPP, N=19; PLL, N=19) | 1 | 0 |
The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Overall Treatment Difference in LSMeans of Beck Depression Inventory Second Edition (BDI-II) Total Score | 4.41 ± 0.39 | 4.29 ± 0.39 |
The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| Minimal at Screening (LPP, N=21; PLL, N=21) | 21 | 20 |
| Minimal at Baseline (LPP, N=21; PLL, N=21) | 21 | 20 |
| Minimal, end of Period 1 (LPP, N=21; PLL, N=21) | 21 | 19 |
| Minimal, end of Period 2 (LPP, N=19; PLL, N=20) | 19 | 20 |
| Minimal, end of Period 3 (LPP, N=19; PLL, N=19) | 19 | 19 |
| Mild at Screening (LPP, N=21; PLL, N=21) | 0 | 1 |
| Mild at Baseline (LPP, N=21; PLL, N=21) | 0 | 1 |
| Mild, end of Period 1 (LPP, N=21; PLL, N=21) | 0 | 1 |
| Mild, end of Period 2 (LPP, N=19; PLL, N=20) | 0 | 0 |
| Mild, end of Period 3 (LPP, N=19; PLL, N=19) | 0 | 0 |
| Moderate at Screening (LPP, N=21; PLL, N=21) | 0 | 0 |
| Moderate at Baseline (LPP, N=21; PLL, N=21) | 0 | 0 |
| Moderate, end of Period 1 (LPP, N=21; PLL, N=21) | 0 | 1 |
| Moderate, end of Period 2 (LPP, N=19; PLL, N=20) | 0 | 0 |
| Moderate, end of Period 3 (LPP, N=19; PLL, N=19) | 0 | 0 |
| Severe at Screening (LPP, N=21; PLL, N=21) | 0 | 0 |
| Severe at Baseline (LPP, N=21; PLL, N=21) | 0 | 0 |
| Severe, end of Period 1 (LPP, N=21; PLL, N=21) | 0 | 0 |
| Severe, end of Period 2 (LPP, N=19; PLL, N=20) | 0 | 0 |
| Severe, end of Period 3 (LPP, N=19; PLL, N=19) | 0 | 0 |
Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline (Day 0) and at each clinic visit (at least every 4 weeks) or at premature discontinuation. Values of the EQ-5D index score range from -1 (worst) to 1 (best).
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Index Scores | 0.82 ± 0.01 | 0.81 ± 0.01 |
At the end of each period, patients rated their overall satisfaction with study treatment using a 5-point categorical scale indicating: 0 - very dissatisfied; 1 - dissatisfied; 2 - no preference; 3 - satisfied; and 4 - very satisfied.
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| 4-Very Satisfied, Period 1 (LPP, N=21; PLL, N=21) | 12 | 9 |
| 4-Very Satisfied, Period 2 (LPP, N=19; PLL, N=20) | 8 | 10 |
| 4-Very Satisfied, Period 3 (LPP, N=19; PLL, N=20) | 12 | 12 |
| 3-Satisfied, Period 1 (LPP, N=21; PLL, N=21) | 7 | 8 |
| 3-Satisfied, Period 2 (LPP, N=19; PLL, N=20) | 9 | 6 |
| 3-Satisfied, Period 3 (LPP, N=19; PLL, N=20) | 5 | 6 |
| 2-No Preference, Period 1 (LPP, N=21; PLL, N=21) | 1 | 3 |
| 2-No Preference, Period 2 (LPP, N=19; PLL, N=20) | 0 | 3 |
| 2-No Preference, Period 3 (LPP, N=19; PLL, N=20) | 1 | 1 |
| 1-Dissatisfied, Period 1 (LPP, N=21; PLL, N=21) | 1 | 1 |
| 1-Dissatisfied, Period 2 (LPP, N=19; PLL, N=20) | 2 | 0 |
| 1-Dissatisfied, Period 3 (LPP, N=19; PLL, N=20) | 0 | 0 |
| 0-Very Dissatisfied, Per. 1 (LPP, N=21; PLL, N=21) | 0 | 0 |
| 0-Very Dissatisfied, Per. 2 (LPP, N=19; PLL, N=20) | 0 | 1 |
| 0-Very Dissatisfied, Per. 3 (LPP, N=19; PLL, N=19) | 1 | 0 |
At the end of each period, investigators rated their overall satisfaction with study treatment using a 5-point categorical scale ranging from 0 (very dissatisfied) to 4 (very satisfied).
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| 4-Very Satisfied, Period 1 (LPP, N=21; PLL,N=21) | 7 | 6 |
| 4-Very Satisfied, Period 2 (LPP, N=19; PLL, N=20) | 5 | 8 |
| 4-Very Satisfied, Period 3 (LPP, N=19; PLL, N=19) | 8 | 11 |
| 3-Satisfied, Period 1 (LPP, N=21; PLL,N=21) | 8 | 9 |
| 3-Satisfied, Period 2 (LPP, N=19; PLL, N=20) | 11 | 10 |
| 3-Satisfied, Period 3 (LPP, N=19; PLL, N=19) | 9 | 5 |
| 2-No Preference, Period 1 (LPP, N=21; PLL,N=21) | 1 | 1 |
| 2-No Preference, Period 2 (LPP, N=19; PLL, N=20) | 1 | 1 |
| 2-No Preference, Period 3 (LPP, N=19; PLL, N=19) | 1 | 2 |
| 1-Dissatisfied, Period 1 (LPP, N=21; PLL,N=21) | 4 | 5 |
| 1-Dissatisfied, Period 2 (LPP, N=19; PLL, N=20) | 2 | 0 |
| 1-Dissatisfied, Period 3 (LPP, N=19; PLL, N=19) | 0 | 1 |
| 0-Very Dissatisfied, Period 1 (LPP,N=21; PLL,N=21) | 1 | 0 |
| 0-Very Dissatisfied, Period 2 (LPP,N=19; PLL,N=20) | 0 | 1 |
| 0-Very Dissatisfied, Period 3 (LPP,N=19; PLL,N=19) | 1 | 0 |
Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Values of the continuous EQ-5D health state today (VAS) ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Health Status Today Using a Visual Analog Scale (VAS) | 81.1 ± 1.25 | 79.4 ± 1.26 |
Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Categories included Better, Much the Same, and Worse.
| Participants | Sequence: Lidoderm - Placebo - Placebo (LPP) | Sequence: Placebo - Lidoderm - Lidoderm (PLL) |
|---|---|---|
| Better Baseline (LPP, N=21; PLL, N=21) | 11 | 4 |
| Better Period 1 (LPP, N=21; PLL, N=21) | 7 | 5 |
| Better Period 2 (LPP, N=19; PLL, N=20) | 8 | 4 |
| Better Period 3 (LPP, N=19; PLL, N=19) | 9 | 6 |
| Much the Same Baseline (LPP, N=21; PLL, N=21) | 10 | 17 |
| Much the Same Period 1 (LPP, N=21; PLL, N=21) | 14 | 15 |
| Much the Same Period 2 (LPP, N=19; PLL, N=20) | 10 | 16 |
| Much the Same Period 3 (LPP, N=19; PLL, N=19) | 9 | 12 |
| Worse Baseline (LPP, N=21; PLL, N=21) | 0 | 0 |
| Worse Period 1 (LPP, N=21; PLL, N=21) | 0 | 1 |
| Worse Period 2 (LPP, N=19; PLL, N=20) | 1 | 0 |
| Worse Period 3 (LPP, N=19; PLL, N=19) | 0 | 1 |
The VSH Sleep Scale is contained in a 15 item self-report instrument that measures the quality of a patient's sleep over the last 24 hours. Each item is scored on a 0-100 visual analog scale. The VSH is categorized into 3 sleep scales: disturbance (which measures delays and interruptions in sleep)\[maximum score = 700\], effectiveness (which measures how well sleep refreshed the individual) \[maximum score = 600\], and supplementation (which measures the need for napping) \[maximum score = 400\]. The higher the score the greater the value of the sleep characteristic for that patient.
| Units on a scale | Lidoderm (Lidocaine 5% Patch) | Placebo Patch |
|---|---|---|
| Disturbance | 246 ± 13.7 | 224 ± 13.9 |
| Effectiveness | 303 ± 9.69 | 302 ± 9.85 |
| Supplementation | 49.7 ± 7.62 | 41.4 ± 7.76 |
Collected over All adverse events (AEs) were recorded from the beginning of the active Run-in Period through 30 days post-study completion/early termination; a period lasting up to 20 weeks in total.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-In Period With Lidoderm (Lidocaine 5% Patch) | — | 1/169 (0.6%) | 51/169 (30.2%) |
| Double-Blind Treatment Period With Lidoderm | — | 1/91 (1.1%) | 24/91 (26.4%) |
| Double-Blind Active Treatment Period With Placebo | — | 1/91 (1.1%) | 23/91 (25.3%) |
| Event | Run-In Period With Lidoderm (Lidocaine 5% Patch) | Double-Blind Treatment Period With Lidoderm | Double-Blind Active Treatment Period With Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/169 | 0/91 | 1/91 |
| Supraventricular extrasystolesCardiac disorders | 0/169 | 1/91 | 0/91 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/169 | 0/91 | 1/91 |
| Event | Run-In Period With Lidoderm (Lidocaine 5% Patch) | Double-Blind Treatment Period With Lidoderm | Double-Blind Active Treatment Period With Placebo |
|---|---|---|---|
| Application site reactionGeneral disorders | 1/169 | 4/91 | 1/91 |
| NasopharyngitisInfections and infestations | 3/169 | 2/91 | 3/91 |
| SinusitisInfections and infestations | 2/169 | 2/91 | 3/91 |
| Application site erythemaGeneral disorders | 2/169 | 1/91 | 2/91 |
| Upper respiratory tract infectionInfections and infestations | 1/169 | 2/91 | 0/91 |
| DiarrhoeaGastrointestinal disorders | 2/169 | 0/91 | 2/91 |
| HeadacheNervous system disorders | 3/169 | 1/91 | 0/91 |
| Application site dermatitisGeneral disorders | 2/169 | 0/91 | 0/91 |
| Oedema peripheralGeneral disorders | 2/169 | 1/91 | 0/91 |
| PainGeneral disorders | 2/169 | 0/91 | 0/91 |
| Age, Continuous(years) | Sequence: Lidoderm - Placebo - Placebo | Sequence: Placebo - Lidoderm - Lidoderm | Total |
|---|---|---|---|
| Mean | 61.1 ± 10.0 | 61.1 ± 10.9 | 61.1 ± 10.4 |
| Sex: Female, Male(Participants) | Sequence: Lidoderm - Placebo - Placebo | Sequence: Placebo - Lidoderm - Lidoderm | Total |
|---|---|---|---|
| Female | 32 | 28 | 60 |
| Male | 18 | 15 | 33 |
| Region of Enrollment(participants) | Sequence: Lidoderm - Placebo - Placebo | Sequence: Placebo - Lidoderm - Lidoderm | Total |
|---|---|---|---|
| United States | 50 | 43 | 93 |
The record gives a start of Mar 2007, a primary completion of Jun 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidoderm